119 related articles for article (PubMed ID: 26786928)
1. Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.
Indini A; Di Nicola M; Del Vecchio M; De Braud F
J Clin Oncol; 2016 Mar; 34(9):1017-8. PubMed ID: 26786928
[No Abstract] [Full Text] [Related]
2. Reply to A. Indini et al.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2016 Mar; 34(9):1018-9. PubMed ID: 26786917
[No Abstract] [Full Text] [Related]
3. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
5. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
Koch C; Paetzold S; Trojan J
Gastroenterology; 2012 Aug; 143(2):298, 504, 505. PubMed ID: 22709738
[No Abstract] [Full Text] [Related]
6. Polymyalgia rheumatica occurring during treatment with ipilimumab.
Maniu C; Kobe C; Schlaak M; Mauch C; Eming SA
Eur J Dermatol; 2016 Oct; 26(5):513-514. PubMed ID: 27349150
[No Abstract] [Full Text] [Related]
7. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.
Maur M; Tomasello C; Frassoldati A; Dieci MV; Barbieri E; Conte P
J Clin Oncol; 2012 Feb; 30(6):e76-8. PubMed ID: 22203769
[No Abstract] [Full Text] [Related]
8. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
[TBL] [Abstract][Full Text] [Related]
9. Novel melanoma therapies and their side effects.
González N; Ratner D
Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
[TBL] [Abstract][Full Text] [Related]
10. Nursing management of patients with metastatic melanoma receiving ipilimumab.
Bryce J; Passoni C
Oncol Nurs Forum; 2013 May; 40(3):215-8. PubMed ID: 23615135
[No Abstract] [Full Text] [Related]
11. Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.
Kopecký J; Trojanová P; Kubeček O; Kopecký O
Jpn J Clin Oncol; 2015 Apr; 45(4):381-4. PubMed ID: 25583422
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab-induced hypophysitis: early Australian experience.
De Sousa SM; Long GV; Tonks KT
Med J Aust; 2014 Aug; 201(4):198-9. PubMed ID: 25164840
[No Abstract] [Full Text] [Related]
14. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
[No Abstract] [Full Text] [Related]
15. [Possible Pitfalls of Ipilimumab Therapy in Malignant Melanoma - a Case Report].
Kopecký J; Kubeček O; Gabalec F; Hoffmann P; Svilias I
Klin Onkol; 2015; 28(6):444-9. PubMed ID: 26673995
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
17. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
18. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
19. First report of ipilimumab-induced Grover disease.
Munoz J; Guillot B; Girard C; Dereure O; Du-Thanh A
Br J Dermatol; 2014 Nov; 171(5):1236-7. PubMed ID: 24749658
[No Abstract] [Full Text] [Related]
20. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
Dick J; Enk A; Hassel JC
Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
